Core Viewpoint - The personalized neoantigen vaccine developed by Dana-Farber Cancer Institute shows significant potential in inducing strong immunity in melanoma patients, although its immunogenicity still requires enhancement [1][2]. Group 1 - The study published in the journal Cell highlights the development of a multi-adjuvant personalized neoantigen vaccine that effectively stimulates immunity in melanoma patients [1][2]. - The research involved testing a long peptide vaccine on 10 melanoma patients, utilizing two adjuvants, Montanide and poly-ICLC, in conjunction with local injection of Ipilimumab and systemic use of Nivolumab [4]. - Among the 9 patients who completed vaccination, the personalized vaccines induced ex vivo T cell responses targeting most neoantigens, with 6 patients generating ex vivo CD8+ T cell responses [5]. Group 2 - Key findings of the study include the ability of most neoantigens to induce ex vivo T cell responses, including CD8+ cell responses [8]. - The vaccine induced dynamic changes in myeloid cell populations at the injection site [8]. - The neoantigen vaccination reshaped the T cell receptor repertoire specific to tumors beyond anti-PD-1 treatment, revealing vaccine-specific tumor-infiltrating lymphocytes (TIL) through TCR reconstruction and antigen screening [8].
Cell:多佐剂新抗原疫苗,在癌症患者中激发强效免疫
生物世界·2025-07-12 01:26